To whom it may concern,

This letter is written in reference to [patient name]. (S)he is a [age]-year-old [race] [male/female] diagnosed with Erdheim-Chester Disease. Erdheim-Chester Disease is a non-Langerhans form of systemic histiocytosis. This progressive disease affects multiple organs and is fatal in 40% of patients in less than three years. Currently, there are not approved treatments for Erdheim-Chester disease. Interferon-α can be considered the first line therapy, but its effects on central nervous system and cardiovascular localization have been shown to be often poor. In this context a combined treatment with the anti-TNFα monoclonal antibody infliximab and methotrexate seems to be effective and well tolerated. Aggressive therapy is warranted in [patient name] as she/he has [pulmonary, cardiac, neurological] involvement, which portend the worst prognosis. [Patient name] has [provide brief summary of therapies tried and their result, focusing on why cladiribine is the correct therapy.] I therefore request that you authorize use of methotrexate.

If you have any questions, comments, or concerns, please feel free to contact me.

Best regards,